Valbiotis SA
EPA:ALVAL.PA
1.18 (EUR) • At close November 13, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Valbiotis SA |
Symbool | ALVAL.PA |
Munteenheid | EUR |
Prijs | 1.178 |
Beurswaarde | 18,587,958 |
Dividendpercentage | 0% |
52-weken bereik | 1.07 - 6.42 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sebastien Peltier HDR, Ph.D. |
Website | https://www.valbiotis.com |
An error occurred while fetching data.
Over Valbiotis SA
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)